Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Block Drug

This article was originally published in The Tan Sheet

Executive Summary

Acquires license to a "topical consumer product" from Boothwyn, Penn.-based start-up Affinity Biotech in exchange for an upfront licensing fee, milestone payments and royalties on sales, Affinity said Sept. 24. The company predicted that the undisclosed product could reach the market as early as next year in a market estimated at $100 mil. Block Drug separately announced Sept. 20 that it anticipates a decline in earnings for the fiscal year ending March 31, 1994 due to unfavorable exchange rates, a weaker economy and "a major spending program to increase advertising and promotion behind core" products.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel